Talaris Therapeutics Shares Owned By Insiders vs. Current Ratio
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
For Talaris Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Talaris Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Talaris Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Talaris Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Talaris Therapeutics over time as well as its relative position and ranking within its peers.
Talaris |
Talaris Therapeutics Current Ratio vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Talaris Therapeutics's current stock value. Our valuation model uses many indicators to compare Talaris Therapeutics value to that of its competitors to determine the firm's financial worth. Talaris Therapeutics is rated below average in shares owned by insiders category among its peers. It is rated third in current ratio category among its peers fabricating about 2.43 of Current Ratio per Shares Owned By Insiders. Comparative valuation analysis is a catch-all technique that is used if you cannot value Talaris Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Talaris Current Ratio vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Talaris Therapeutics |
| = | 11.90 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Talaris Therapeutics |
| = | 28.92 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Talaris Current Ratio Comparison
Talaris Therapeutics is currently under evaluation in current ratio category among its peers.
Talaris Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Talaris Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Talaris Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Talaris Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Talaris Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky. Talaris Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 128 people.
Talaris Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Talaris Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Talaris Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Talaris Therapeutics' important profitability drivers and their relationship over time.
Use Talaris Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Talaris Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Talaris Therapeutics will appreciate offsetting losses from the drop in the long position's value.Talaris Therapeutics Pair Trading
Talaris Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Talaris Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Talaris Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Talaris Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Talaris Therapeutics to buy it.
The correlation of Talaris Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Talaris Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Talaris Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Talaris Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Talaris Therapeutics position
In addition to having Talaris Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Dividend Beast Thematic Idea Now
Dividend Beast
An experimental equal-weighted theme of equities with high dividend yield and solid fundamentals based on Macroaxis rating system. The Dividend Beast theme has 69 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Dividend Beast Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |